Compare GROY & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GROY | RXST |
|---|---|---|
| Founded | 2020 | 1997 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 618.0M | 513.1M |
| IPO Year | 2021 | 2021 |
| Metric | GROY | RXST |
|---|---|---|
| Price | $4.09 | $12.73 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 11 |
| Target Price | $5.00 | ★ $11.30 |
| AVG Volume (30 Days) | ★ 3.6M | 850.9K |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $14,464,000.00 | ★ $142,085,000.00 |
| Revenue This Year | $71.94 | N/A |
| Revenue Next Year | $66.48 | $4.18 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 86.30 | 10.75 |
| 52 Week Low | $1.16 | $6.32 |
| 52 Week High | $4.49 | $39.37 |
| Indicator | GROY | RXST |
|---|---|---|
| Relative Strength Index (RSI) | 54.72 | 70.03 |
| Support Level | $3.96 | $11.84 |
| Resistance Level | $4.49 | $13.22 |
| Average True Range (ATR) | 0.25 | 0.64 |
| MACD | -0.01 | 0.10 |
| Stochastic Oscillator | 59.09 | 84.76 |
Gold Royalty Corp is a precious metals-focused royalty and mineral streaming company. The company offers creative financing solutions to the metals and mining industry. The company's mission is to acquire royalties, streams and similar interests at varying stages of the mine life cycle to build a balanced portfolio offering near, medium and longer-term attractive returns for investors. It has its business as a single operating segment, being the investment in royalty and mineral stream interests. The company derives maximum revenue from Canada.
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.